BDBM454200 US10717708, Example 176::US11186544, Example 176::US11530183, Example 176

SMILES COc1ccc(NC(=O)N[C@@H]2CCCN(C2=O)c2ccc(cc2)-c2ccccc2C(N)=O)cc1Cl

InChI Key InChIKey=SJYNWIVHSSCSHL-UHFFFAOYSA-N

Data  8 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 454200   

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  780nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  1.20E+3nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  780nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  1.20E+3nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  780nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2022
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  1.20E+3nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2022
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  780nMAssay Description:Agonist activity at human FPR2 expressed in CHO cells assessed as cAMP level incubated for 1.5 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  1.20E+3nMAssay Description:Agonist activity at human FPR1 expressed in CHO cells assessed as cAMP level incubated for 1.5 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed